What happens if a patient's insurance stops covering Wegovy mid-treatment?

If your insurance stops covering Wegovy, you may face high out-of-pocket costs. Options include appealing the denial, using savings programs, or discussing alternatives.

Why Insurance Coverage for Wegovy Can Change

Insurance plan formularies—the list of covered drugs—are updated annually. Your employer may switch to a new insurance plan with different coverage, or your current plan may remove Wegovy from its formulary for the upcoming year, leading to a loss of coverage.

A common reason for coverage loss is the expiration of a prior authorization (PA). PAs are typically granted for 6 to 12 months. When it's time for renewal, your insurer may have new requirements, such as achieving a certain percentage of weight loss, that you must meet to continue coverage.

Changes in your personal circumstances, such as switching jobs or retiring, often result in a new health insurance provider. This new plan may not cover Wegovy or may classify it as a non-preferred brand, subjecting it to higher co-pays or different authorization criteria.

Insurers may also implement new 'step therapy' protocols. This requires you to try and fail one or more lower-cost alternative medications before they will approve coverage for a more expensive drug like Wegovy, even if you were previously stable on it.

First Steps After a Coverage Denial

The first step is to contact your insurance company directly. Request a formal letter of denial that clearly explains why coverage for Wegovy has been discontinued. This documentation is essential for any appeal.

Immediately inform your prescribing physician's office. They are your most important ally in this process. Their clinical staff often has experience with insurance appeals and can guide you on the necessary steps.

Your physician can submit an appeal on your behalf, which typically includes a letter of medical necessity. This letter details your treatment history, the clinical benefits you've experienced (such as weight loss and improved metabolic health), and the medical risks of abruptly stopping the medication.

The appeals process can have multiple levels. If the initial appeal is denied, you may have the right to an internal review by the insurance company and potentially an external review by an independent third party. Persistence is often necessary to overturn a denial.

Reducing Out-of-Pocket Costs for Wegovy

Novo Nordisk, the manufacturer of Wegovy, offers a savings card for commercially insured patients. If your insurance denies coverage, this card can reduce the cost by up to $500 per 28-day supply. However, with a list price over $1,300, the remaining out-of-pocket expense can still be substantial.

For patients with limited income who are uninsured or have government-sponsored insurance like Medicare, Novo Nordisk has a Patient Assistance Program (PAP). This program may provide Wegovy at no cost to eligible individuals who meet specific income and other requirements.

Prescription discount services like GoodRx may offer coupons. While these can provide some savings, they typically do not bring the cost of brand-name GLP-1 medications like Wegovy into an affordable range for most people paying entirely out-of-pocket.

Always discuss your financial constraints with your physician. They may be aware of other local programs or be able to provide samples to bridge a short gap in coverage while you navigate your options.

What Happens Clinically If You Stop Wegovy?

Wegovy (semaglutide) is a GLP-1 receptor agonist that works by suppressing appetite and promoting feelings of fullness. When the medication is stopped, these effects cease, often leading to a rapid return of hunger and food cravings.

Clinical evidence confirms this effect. The STEP 1 trial extension study followed participants after they stopped taking semaglutide. Within one year of discontinuation, participants regained, on average, two-thirds of the weight they had lost while on the medication.

This weight regain is a physiological response to the absence of the drug's effect on appetite-regulating hormones; it is not a matter of willpower or personal failure. It underscores that obesity is a chronic condition that often requires long-term treatment.

Beyond weight regain, stopping Wegovy can also reverse improvements in cardiometabolic risk factors like blood pressure, cholesterol levels, and blood sugar control that were achieved during treatment.

Discussing Treatment Alternatives with Your Physician

If Wegovy is no longer a viable option due to cost, it is crucial to work with your doctor on a new treatment plan. Other FDA-approved medications for chronic weight management, such as Zepbound (tirzepatide), Contrave, or Qsymia, may be covered by your insurance.

A physician-supervised medical [weight loss](/weight-loss) program can help you transition to a new treatment plan smoothly. This ensures your care is managed by a professional who understands your medical history and weight management goals.

In some cases, your physician may determine that a compounded medication containing semaglutide is an appropriate option for you. These medications are prepared by licensed U.S. pharmacies to meet the specific needs of a patient based on a doctor's prescription.

It is important to understand that compounded drugs are not FDA-approved. They do not undergo the same pre-market review for safety, efficacy, and quality as brand-name drugs like Wegovy.

Bottom Line

Losing insurance coverage for Wegovy mid-treatment is a common and difficult situation. The key is to take swift, informed action to protect your health and progress.

Your first steps should be to formally appeal the insurance denial with help from your doctor's office. Simultaneously, investigate all financial assistance programs, including manufacturer savings cards and Patient Assistance Programs, being mindful of their limitations.

If you are unable to regain coverage or afford the out-of-pocket cost, work closely with your physician to create a sustainable long-term plan. This may involve switching to a different FDA-approved medication or exploring other physician-supervised options to ensure continuity of care.

This article is for educational purposes only and not a substitute for professional medical advice.

Drafted by the GOAL.MD Authority Engine and approved editorially by GOAL.MD staff. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.